Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug approvals and failures: implications for alliances

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. No Author listed. 1Q Stock Wrap-Up. BioCentury 14, No.15, 9–11 (2006).

  2. No Author listed. 2Q Stock Wrap-Up. BioCentury 14, No. 29, 10–13 (2006).

  3. No Author listed. 3Q Stock Wrap Up. BioCentury 14, No. 43, 10–13 (2006).

  4. Edelson, S. 4Q Stock Wrap-Up. BioCentury 15, No. 1, 8–12 (2007).

    Google Scholar 

  5. No Author listed. 1Q Stock Wrap-Up. BioCentury 15, No. 15, 9–12 (2007).

  6. Lawrence S. 2Q Stock Wrap-Up. BioCentury 15, No. 29, 10–13 (2007).

  7. Lawrence, S. 3Q Stock-Wrap-Up. BioCentury 15 No. 43, 9–12 (2007).

    Google Scholar 

  8. Lawrence, S. 4Q Stock Wrap-Up. BioCentury 16 No. 2, 20–25 (2008).

    Google Scholar 

  9. Sabo, S. The current status of targeted therapies for breast cancer: an interview with Kathy Miller, MD. Medscape web site [online], (2003).

    Google Scholar 

  10. Keymeulen, B. et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352, 2598–2608 (2005).

    Article  CAS  Google Scholar 

  11. Drews, J. & Ryser, S, Innovation deficit in the pharmaceutical industry. Drug Inf. J. 30, 97–107 (1996).

    Article  Google Scholar 

Download references

Author information


Supplementary information

Supplementary information S1 (table)

US FDA drug approvals from January 2006–December 2007 (PDF 343 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Czerepak, E., Ryser, S. Drug approvals and failures: implications for alliances. Nat Rev Drug Discov 7, 197–198 (2008).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing